Guidance, NICE advice and quality standards in development | Guidance

Showing 431 to 440 of 453

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]	Technology appraisal guidance	TBC
Type 2 diabetes in adults: management (medicines update)	NICE guideline	18 February 2026
Upadacitinib for treating giant cell arteritis [ID6299]	Technology appraisal guidance	21 May 2026
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]	Technology appraisal guidance	TBC
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]	Technology appraisal guidance	TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC
VER-01 for treating chronic low back pain [ID6638]	Technology appraisal guidance	TBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]	Technology appraisal guidance	TBC